Researchers Behind COVID-19 RECOVERY Trial Launch New Monkeypox Treatment Trial
The U.K.-based Oxford University researchers behind the COVID-19 treatment trial RECOVERY are back again, this time for a randomized…
Bristol Myers Squibb Secures Canadian Regulatory Nod For Lung Cancer Candidate In Neoadjuvant Setting
Health Canada announced approval for Bristol Myers Squibb’s (NASDAQ: BMY) OPDIVO (nivolumab) 360 mg (injection for intravenous use) in combination with platinum-doublet chemotherapy every three weeks for three cycles in adult patients with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setti
Intellia Therapeutics To Present Interim Clinical Data From Ongoing Phase 1/2 Study Of NTLA-2002 For Treatment Of Hereditary Angioedema At 2022 Bradykinin Symposium
First clinical data on safety and activity of NTLA-2002, Intellia's second systemically administered in vivo CRISPR candidate
This COVID-19 Shot Stock Could Have Eye Disease Gene Therapy As Significant Driver, Mizuho Analyst Says
Mizuho initiated coverage on Ocugen Inc (NASDAQ:OCGN) with a Buy rating and a price target of $5, reflecting an upside of almost…
KalVista Shares Climb As Late-Stage Label Extension Study On Skin Disorder Candidate Kicks-off
KalVista Pharmaceuticals (NASDAQ: KALV) has initiated the KONFIDENT-S open label extension (OLE) study for its ongoing Phase 3 study of sebetralstat for the on-demand treatment of hereditary angioedema (HAE) attacks.
Ensysce Biosciences Announces Completion Of Clinical Portion Of Human Abuse Potential Trial PF614-103
Completion of Clinical Portion Represents Critical Milestone Towards Commercialization
Nasal Opioid Abuse Being Explored for PF614
Data From Trial Expected in September 2022
Inhibikase Therapeutics Announces Dosing Of First Patient In Its Phase 2a ‘201’ Clinical Trial Of IkT-148009 To Treat Parkinson’s Disease
nhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced dosing of the
Merck Gets FDA Fast Track Status For Chronic Kidney Disease Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Merck's (NYSE: MRK) lead asset MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease (ESRD).
Synlogic Granted FDA Fast Track Designation For SYNB1353 For Treatment Of Homocystinuria (HCU)
CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to
Foghorn Therapeutics Announces FDA Has Placed A Clinical Hold On Phase I Dose Escalation Study Of FHD-286
Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system,